Statement of Changes in Beneficial Ownership (4)
09 10월 2021 - 5:22AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Evans John M. |
2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc.
[
BEAM
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) CEO |
(Last)
(First)
(Middle)
C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET |
3. Date of Earliest Transaction
(MM/DD/YYYY)
10/6/2021 |
(Street)
CAMBRIDGE, MA 02139
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 10/6/2021 | | M(1) | | 27700 | A | $1.03 | 1061225 | D | |
Common Stock | 10/6/2021 | | S(2) | | 3149 | D | $82.72 (3) | 1058076 | D | |
Common Stock | 10/6/2021 | | S(2) | | 13406 | D | $83.47 (4) | 1044670 | D | |
Common Stock | 10/6/2021 | | S(2) | | 10444 | D | $84.45 (5) | 1034226 | D | |
Common Stock | 10/6/2021 | | S(2) | | 701 | D | $85.19 (6) | 1033525 | D | |
Common Stock | 10/6/2021 | | S(2) | | 2171 | D | $82.71 (7) | 200829 | I | By John M. Evans, III 2018 Irrevocable Trust |
Common Stock | 10/6/2021 | | S(2) | | 9863 | D | $83.49 (8) | 190966 | I | By John M. Evans, III 2018 Irrevocable Trust |
Common Stock | 10/6/2021 | | S(2) | | 7566 | D | $84.45 (9) | 183400 | I | By John M. Evans, III 2018 Irrevocable Trust |
Common Stock | 10/6/2021 | | S(2) | | 400 | D | $85.24 (10) | 183000 | I | By John M. Evans, III 2018 Irrevocable Trust |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (Right to Buy) | $1.03 | 10/6/2021 | | M | | | 27700 | (11) | 7/13/2028 | Common Stock | 27700 | $0.00 | 331645 | D | |
Explanation of Responses: |
(1) | The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. |
(2) | The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
(3) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $82.465 to $82.995, inclusive. |
(4) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $83.04 to $83.98, inclusive. |
(5) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $84.005 to $84.98, inclusive. |
(6) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $85.03 to $85.32, inclusive. |
(7) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $82.465 to $82.97, inclusive. |
(8) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $83.08 to $83.98, inclusive. |
(9) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $84.07 to $84.98, inclusive. |
(10) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $85.07 to $85.31, inclusive. |
(11) | The option vests as to 25% on the first anniversary of the of the vesting commencement date, January 8, 2018, and at a rate of 2.78% each month thereafter until the option is fully vested. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Evans John M. C/O BEAM THERAPEUTICS INC. 26 LANDSDOWNE STREET CAMBRIDGE, MA 02139 | X |
| CEO |
|
Signatures
|
By: /s/ Christine Bellon, Attorney-in-fact | | 10/8/2021 |
**Signature of Reporting Person | Date |
Beam Therapeutics (NASDAQ:BEAM)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Beam Therapeutics (NASDAQ:BEAM)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024